Viral Hepatitis

You have full text access to this OnlineOpen article

Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy

  1. Paul J. Pockros M.D.1,†,*,
  2. Mitchell L. Shiffman2,
  3. Eugene R. Schiff3,
  4. Mark S. Sulkowski4,
  5. Zobair Younossi5,
  6. Douglas T. Dieterich6,
  7. Teresa L. Wright7,
  8. Samir H. Mody8,
  9. K. Linda Tang8,
  10. Betty L. Goon8,
  11. Peter J. Bowers9,
  12. Gerhard Leitz8,
  13. Nezam H. Afdhal10

Article first published online: 24 NOV 2004

DOI: 10.1002/hep.20482

Issue

Hepatology

Hepatology

Volume 40, Issue 6, pages 1450–1458, December 2004

Additional Information

How to Cite

Pockros, P. J., Shiffman, M. L., Schiff, E. R., Sulkowski, M. S., Younossi, Z., Dieterich, D. T., Wright, T. L., Mody, S. H., Tang, K. L., Goon, B. L., Bowers, P. J., Leitz, G. and Afdhal, N. H. (2004), Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology, 40: 1450–1458. doi: 10.1002/hep.20482

Author Information

  1. 1

    Scripps Clinic, La Jolla, CA

  2. 2

    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA

  3. 3

    University of Miami School of Medicine, Miami, FL

  4. 4

    Johns Hopkins University School of Medicine, Baltimore, MD

  5. 5

    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA

  6. 6

    Mt. Sinai School of Medicine, New York, NY

  7. 7

    San Francisco VA Hospital, San Francisco, CA

  8. 8

    Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ

  9. 9

    Johnson & Johnson Pharmaceutical Research and Development, Raritan, NJ

  10. 10

    Beth Israel Deaconess Medical Center, Boston, MA

  1. †

    fax: 858-554-8065

*Scripps Clinic, 10666 N. Torrey Pines Road, La Jolla, CA 92037

Publication History

  1. Issue published online: 24 NOV 2004
  2. Article first published online: 24 NOV 2004
  3. Manuscript Accepted: 17 SEP 2004
  4. Manuscript Received: 30 JUN 2004

Funded by

  • Ortho Biotech Clinical Affairs, LLC Bridgewater, NJ

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (221K)

References

  • 1
    Jacobson AM, de Groot M, Samson JA. The evaluation of two measures of quality of life in patients with type I and type II diabetes. Diabetes Care 1994; 17: 267–274.
  • 2
    Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer, E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875–2882.
  • 3
    Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. HEPATOLOGY 2002; 35: 704–708.
    Direct Link:
  • 4
    Ware JE Jr, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. HEPATOLOGY 1999; 30: 550–555.
    Direct Link:
  • 5
    Hunt CM, Dominitiz JA Bute BP, Waters B, Blasi U, Williams DM. Effect of interferon alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997; 42: 2482–2486.
  • 6
    McHutchison JG, Ware, JE, Bayliss MS, Pianko S, Albrecht JK, Cort S, et al. The effects of interferon alfa-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34: 140–147.
  • 7
    Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic patients receiving epoetin alfa therapy. Cancer 2002; 95: 888–895.
    Direct Link:
  • 8
    Rebetron (Rebetol/Intron A) [package insert]. Kenilworth, NJ: Schering Corporation, 2003.
  • 9
    Sulkowski MS, Wasserman R, Brooks LJ, Ball L, Gish R. Changes in hemoglobin during interferon alfa-2b plus ribavirin therapy for chronic hepatitis C viral infection. J Viral Hepat 2004; 11: 243–250.
    Direct Link:
  • 10
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Concales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.
  • 11
    Gaeta GB, Precone DF, Felaco FM, Bruno R, Spadaro A, Stomaiuolo G, et al. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre study in “real world” patients with chronic hepatitis C. Aliment Pharmacol Ther 2002; 16: 1633–1639.
    Direct Link:
  • 12
    McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061–1069.
  • 13
    Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. HEPATOLOGY 2003; 38: 645–652.
    Direct Link:
  • 14
    Shiffman M, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon Alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015–1023.
  • 15
    Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–355.
  • 16
    Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, et al. PROACTIVE Study Group. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126: 1302–1311.
  • 17
    Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center, 1993.
  • 18
    Volberding P. The impact of anemia on quality of life in HIV-infected patients. J Infect Dis 2002; 185(Suppl 2): S110–S114.
  • 19
    Dieterich DT, Wasserman R, Bräu N, Hassanein TI, Bini EJ, Bowers PJ, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98: 2491–2499.
  • 20
    Bonkovsky HL, Wooley JM. The Consensus Interferon Study Group. Reduction in health-related quality of life and improvement with interferon therapy. HEPATOLOGY 1999; 29: 264–270.
    Direct Link:
  • 21
    Obhrai J, Hall Y, Anand BS. Assessment of fatigue and psychologic disturbances in patients with hepatitis C infection. J Clin Gastroenterol 2001; 32: 413–417.
  • 22
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peg-interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for intial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958–965.
  • 23
    Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures. Pharmacoeconomics 1999; 15: 141–155.
  • 24
    Patrick DL, Gagnon DD, Zagari MJ, Mathijs R, Sweetenham J. Epoetin Alfa Study Group. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003; 39: 335–345.
  • 25
    Neary MP, Cort S, Bayliss MS, Ware JE. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis 1999; 19(Suppl 1): 77–85.
View Full Article (HTML) Get PDF (221K)